Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Belinostat: Phase I data

Data from 14 evaluable patients in an ongoing, open-label, dose-escalation Phase I trial showed that IV

Read the full 164 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE